
|Articles|September 25, 2000
Early Approval for Abbott AIDS Medicine
Advertisement
(ABBOTT PARK, ILL)The Food and Drug Administration (FDA) has granted an early approval of the Abbott Laboratories' AIDS drug Kaletra, a form of protease inhibitor medication that has shown considerable promise in bringing the virus down to undetectable levels. Abbott applied for FDA approval on June 1, 2000 and was not expecting results until later this fall.
Kaletra is a mixture of two drugs, the main one generically called lopinavir and previously called ABT-378 in Abbott clinical labs, the other is ritonavir, already on the market as an AIDS drug under the brand name Norvir. For more information visit www.fda.gov.
Advertisement
Advertisement
Advertisement
Trending on Infection Control Today
1
Defunded and Exposed: How US Aid Cuts and Broken Trust Fueled the 2026 Ebola Crisis
2
Influenza Vaccine Study in Older Adults Supports Flexible Vaccine Strategies for Health Systems and Long-Term Care Facilities
3
The MV Hondius: A Case for Real-Time Epidemiological Surveillance
4
Sterile Processing Leaders Call for Greater Autonomy, Education, and Recognition in Patient Safety
5





